Traduction de «product juli » (Néerlandais → Français) :

TERMINOLOGIE

product dat aescine bevat
produit contenant de l'aescine

product dat balsalazide bevat
produit contenant du balsalazide

product dat bacitracine bevat
produit contenant de la bacitracine

product dat barbituraat bevat
produit contenant du barbiturique

product dat basiliximab bevat
produit contenant du basiliximab

product dat baclofen bevat
produit contenant du baclofène

product dat auranofine bevat
produit contenant de l'auranofine

product dat auranofine in orale vorm bevat
produit contenant de l'auranofine sous forme orale

product dat enkel auranofine in orale vorm bevat
produit contenant seulement de l'auranofine sous forme orale

product dat baricitinib bevat
produit contenant du baricitinib

TRADUCTIONS EN CONTEXTE

narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September
narcotics and concerning risk limitation and therapeutic advice and of 22 January 1998 governing certain psychotropic substances and concerning risk limitation and therapeutic advice and of 12 April 1974 containing certain provisions relating to substances with hormonal, antihormonal, anabolic, beta-adrenergic, anti-infectious, antiparasitic and anti-inflammatory action Law of 15 July 1985 on the use in animals of substances with hormonal, anti-hormonal, beta-adrenergic or production stimulating action Law of 13 June 1986 on the removal and transplanting of organs, with regard to cells and tissues Law of 28 August 1991 on the practice of veterinary medicine, regarding the provision of medicines to animal carers Law of 5 July 1994 on blood and blood derivatives of human origin Law of 7 May 2004 on experiments on the human person Royal decree of 31 May 1885 approving new instructions for physicians, pharmacists and druggists Royal decree of 22 September 1966 on the conditions and arrangements for the recognition of laboratories for the analysis and checking of medicines Royal decree of 6 June 1960 on the production, preparation and wholesale distribution and delivery of medicines Royal decree no. 78 of 10 November 1967 on the practice of the healthcare professions regarding the dispensing of medicines to the public and Royal decree of 25 September

Law of 20 July 2006 on the establishment and functioning of the Federal Agency for Medicines and Health Products Royal decrees of 25 February 2007 on the composition and working method of the committees of the Federal Agency for Medicines and Health Products Royal decree of 20 December 2007 determining the date of establishment of the Scientific Committee, namely 1 February 2008 Royal decree of 28 January 2008 on the concrete composition of the Consultative Committee Ministerial decree of 11 January 2007 on the composition and appointment of the members of the executive board of the Federal Agency for Medicines and Health Products
Law of 20 July 2006 on the establishment and functioning of the Federal Agency for Medicines and Health Products Royal decrees of 25 February 2007 on the composition and working method of the committees of the Federal Agency for Medicines and Health Products Royal decree of 20 December 2007 determining the date of establishment of the Scientific Committee, namely 1 February 2008 Royal decree of 28 January 2008 on the concrete composition of the Consultative Committee Ministerial decree of 11 January 2007 on the composition and appointment of the members of the executive board of the Federal Agency for Medicines and Health Products

The FAMHP was established by law on 20 July 2006 and as from 1 January 2007 completely took over the role and fields of competency of the Directorate-General for Medicinal Products (DG Medicinal Products) that was a part of the Federal Public Service (FPS) Public Health, Food Chain Security and Environment.
The FAMHP was established by law on 20 July 2006 and as from 1 January 2007 completely took over the role and fields of competency of the Directorate-General for Medicinal Products (DG Medicinal Products) that was a part of the Federal Public Service (FPS) Public Health, Food Chain Security and Environment.

De apotheker kan het product vanuit het buitenland importeren, mits respecteren van de daarvoor geldende procedure (bv. voorschrift van de arts op naam van de patiënt en artsenverklaring) [zie Folia juli 2004 ].
Le pharmacien peut importer le produit de l’étranger, à condition de respecter la procédure d’application en la matière (p. ex. prescription médicale au nom du patient et déclaration du médecin) [voir Folia de juillet 2004 ].

- De “hulpstoffen met erkende werking” (met de toedieningsweg en de drempelwaarde vanaf dewelke effecten mogelijk zijn, en met uitleg over de risicogroepen) zijn gedefinieerd in het richtsnoer van de Europese Commissie “Excipients in the label and package leaflet of medicinal product for human use” (juli 2003, te raadplegen via [http ...]
- Les « excipients à effet notoire » (avec la voie d’administration et la valeur-seuil à partir de laquelle des effets sont possibles, ainsi que des explications sur les groupes à risque) sont définis dans une directive de la Commission européenne “Excipients in the label and package leaflet of medicinal product for human use” (juillet 2003, à consulter sur [http ...]

De apotheker kan het product vanuit het buitenland importeren, mits respecteren van de daarvoor geldende procedure (bv. voorschrift van de arts op naam van de patiënt en artsenverklaring) [zie Folia juli 2004].
Le pharmacien peut importer le produit de l’étranger, à condition de respecter la procédure d’application en la matière (p. ex. prescription médicale au nom du patient et déclaration du médecin) [voir Folia de juillet 2004].

De " hulpstoffen met erkende werking" (met de toedieningsweg en de drempelwaarde vanaf dewelke effecten mogelijk zijn, en met uitleg over de risicogroepen) zijn gedefinieerd in het richtsnoer van de Europese Commissie " Excipients in the label and package leaflet of medicinal product for human use" (juli 2003, te raadplegen via [http ...]
Les " excipients à effet notoire " (avec la voie d’administration et la valeur-seuil à partir de laquelle des effets sont possibles, ainsi que des explications sur les groupes à risque) sont définis dans une directive de la Commission européenne " Excipients in the label and package leaflet of medicinal product for human use" (juillet 2003, à consulter sur [http ...]

Achtereenvolgens wordt stilgestaan bij de productnaam “ het voedingssupplement “Homeoter en Biokruiden Special”, het gebruik van het product, de door het FAVV ondernomen maatregelen en de wettelijke situering ( toepassing van art. 3,§ 1 van de wet van 15 juli 1985 betreffende het gebruik bij dieren van stoffen met hormonale, anti-hormonale, beta-adrenergische of productie-stimulerende werking) en de procedures die daaruit voortvloeien.
On aborde successivement le nom du produit “le complément alimentaire « Homeoter” et “biokruiden special », l’utilisation du produit, les mesures prises par l’AFSCA et la situation légale (application de l’art. 3, § 1 de la loi du 15 juillet 1985 relative à l’utilisation de substances à effet hormonal, à effet antihormonal, à effet bêta-adrénergique ou à effet stimulateur de production chez les animaux), ainsi que les procédures qui en découlent.

Amendments to the Law of 20 July 2006 on the establishment and functioning of the Federal Agency for Medicines and Health Products (art. 178-180).
Amendments to the Law of 20 July 2006 on the establishment and functioning of the Federal Agency for Medicines and Health Products (art. 178-180).

Amendments to the Law of 20 July 2006 on the establishment and functioning of the Federal Agency for Medicines and Health Products (art. 109).
Amendments to the Law of 20 July 2006 on the establishment and functioning of the Federal Agency for Medicines and Health Products (art. 109).